You beat me to it!

$CVOL - Wants to go even lower

$IDI, Dr. Frost play, announced it will be included in Russell Microcap Index yesterday

$IDI - IDI, Inc. Announces Its Inclusion in the Russell Microcap Index(R)

7:30 AM ET 6/23/15 | BusinessWire

IDI, Inc. (NYSE MKT: IDI), an information solutions provider and multi-platform media company, today announced that it has been added to the Russell Microcap Index(R) following the conclusion of the Russell indexes annual reconstitution on June 26, 2015, according to the update of the preliminary list of reconstitution additions and deletions posted on June 19, 2015.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

"We are extremely pleased to join the Russell Microcap Index(R) as it strongly coincides with our increased efforts to broaden our shareholder base and share our redefined growth strategy with the investment community," stated Mr. Derek Dubner, Co-CEO of IDI, Inc. "We look forward to building upon our new position within the data fusion space and sharing our progress with now a greater investor audience as we move forward."

About IDI, Inc.

IDI, Inc. is an information solutions provider focused on the multi-billion dollar data-fusion market. IDI delivers otherwise unattainable insight into the ever-expanding universe of consumer- and business-centric data. Through proprietary linking technology, advanced systems architecture, and a massive data repository, IDI will address the rapidly growing need for actionable intelligence to support the entirety of the risk management industry, for purposes including due diligence, risk assessment, fraud detection and prevention, authentication and verification, and more. Additionally, IDI's cross-functional core systems and processes are designed to deliver an unrivaled level of clarity into consumer data to support advanced marketing analytics. IDI also operates a multi-platform media company operating in China, which provides advertising services in the out-of-home advertising industry, including iScreen Outdoor LCD screens and billboards.

FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipate," "believes," "should," "intends," "estimates," and other words of similar meaning. Such forward looking statements include statements about whether joining the Russell Microcap Index(R) will coincide with our efforts to broaden our shareholder base and growth strategy with the investment community. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risks set forth in IDI's Annual Report on 10-K, filed with the SEC on April 15, 2015, as well as the other factors described in the filings that IDI makes with the SEC from time to time. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150623005516r1&sid=cmtx6&distro=nx&lang=en

View source version on businesswire.com: http://www.businesswire.com/news/home/20150623005516/en/

SOURCE: IDI, Inc.

For IDI, Inc.
MDM Worldwide Solutions
David Zazoff, 646-403-3554

IDI, Inc. Announces Its Inclusion in the Russell Microcap Index(R)

7:30 AM ET 6/23/15 | BusinessWire

IDI, Inc. (NYSE MKT: IDI), an information solutions provider and multi-platform media company, today announced that it has been added to the Russell Microcap Index(R) following the conclusion of the Russell indexes annual reconstitution on June 26, 2015, according to the update of the preliminary list of reconstitution additions and deletions posted on June 19, 2015.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

"We are extremely pleased to join the Russell Microcap Index(R) as it strongly coincides with our increased efforts to broaden our shareholder base and share our redefined growth strategy with the investment community," stated Mr. Derek Dubner, Co-CEO of IDI, Inc. "We look forward to building upon our new position within the data fusion space and sharing our progress with now a greater investor audience as we move forward."

About IDI, Inc.

IDI, Inc. is an information solutions provider focused on the multi-billion dollar data-fusion market. IDI delivers otherwise unattainable insight into the ever-expanding universe of consumer- and business-centric data. Through proprietary linking technology, advanced systems architecture, and a massive data repository, IDI will address the rapidly growing need for actionable intelligence to support the entirety of the risk management industry, for purposes including due diligence, risk assessment, fraud detection and prevention, authentication and verification, and more. Additionally, IDI's cross-functional core systems and processes are designed to deliver an unrivaled level of clarity into consumer data to support advanced marketing analytics. IDI also operates a multi-platform media company operating in China, which provides advertising services in the out-of-home advertising industry, including iScreen Outdoor LCD screens and billboards.

FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipate," "believes," "should," "intends," "estimates," and other words of similar meaning. Such forward looking statements include statements about whether joining the Russell Microcap Index(R) will coincide with our efforts to broaden our shareholder base and growth strategy with the investment community. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risks set forth in IDI's Annual Report on 10-K, filed with the SEC on April 15, 2015, as well as the other factors described in the filings that IDI makes with the SEC from time to time. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150623005516r1&sid=cmtx6&distro=nx&lang=en

View source version on businesswire.com: http://www.businesswire.com/news/home/20150623005516/en/

SOURCE: IDI, Inc.

For IDI, Inc.
MDM Worldwide Solutions
David Zazoff, 646-403-3554

$NUGT - $8.96 -0.0001 (0.00%) back to par on today's buy...anyone have thoughts one why the seesaw action today?

$RKUS - IS back on my radar

Juniper partners with Ruckus in wake of HP-Aruba deal
Jun 23 2015, 10:54 ET | About: Juniper Networks (JNPR) | By: Eric Jhonsa, SA News Editor

Juniper (JNPR -0.1%) is partnering with carrier/enterprise Wi-Fi hardware and software vendor Ruckus (RKUS +0.7%) to offer enterprise, government, and education clients solutions that pair Juniper's EX Series Ethernet switches with Ruckus' ZoneFlex Wi-Fi access points and SmartZone Wi-Fi management software.

The companies also plan to integrate their security and hardware provisioning tools, and products that lower the number of logical network devices that need to be managed by IT admins.

The alliance comes shortly after HP (a Juniper Ethernet rival) acquired Ruckus rival Aruba Networks. Last year, Juniper announced a partnership with Aruba that bore a strong resemblance to the Ruckus deal. For now, Juniper says Aruba remains a partner.

Dan Ferguson, the CEO of a Juniper channel partner: "Juniper teaming with Ruckus says Juniper is moving away from the Aruba relationship ... Juniper needs to team up with somebody in the wireless space -- they can't go to market with a big hole in their portfolio." Mark Robinson, the president of another channel partner: "It solidifies what everyone was thinking, which was that the whole Juniper-Aruba [relationship] was not going anywhere ... Ruckus has always been perceived positively in the marketplace. I think they're an innovative company."

Juniper partners with Ruckus in wake of HP-Aruba deal
Jun 23 2015, 10:54 ET | About: Juniper Networks (JNPR) | By: Eric Jhonsa, SA News Editor

Juniper (JNPR -0.1%) is partnering with carrier/enterprise Wi-Fi hardware and software vendor Ruckus (RKUS +0.7%) to offer enterprise, government, and education clients solutions that pair Juniper's EX Series Ethernet switches with Ruckus' ZoneFlex Wi-Fi access points and SmartZone Wi-Fi management software.

The companies also plan to integrate their security and hardware provisioning tools, and products that lower the number of logical network devices that need to be managed by IT admins.

The alliance comes shortly after HP (a Juniper Ethernet rival) acquired Ruckus rival Aruba Networks. Last year, Juniper announced a partnership with Aruba that bore a strong resemblance to the Ruckus deal. For now, Juniper says Aruba remains a partner.

Dan Ferguson, the CEO of a Juniper channel partner: "Juniper teaming with Ruckus says Juniper is moving away from the Aruba relationship ... Juniper needs to team up with somebody in the wireless space -- they can't go to market with a big hole in their portfolio." Mark Robinson, the president of another channel partner: "It solidifies what everyone was thinking, which was that the whole Juniper-Aruba [relationship] was not going anywhere ... Ruckus has always been perceived positively in the marketplace. I think they're an innovative company."

$AZUR - Azure Midstream Partners, LP Prices Public Offering of 3,500,000 Common Units

9:29 AM ET 6/17/15 | GlobeNewswire

Azure Midstream Partners, LP (NYSE:AZUR) (the "Partnership") today announced that it has priced its public offering of 3,500,000 common units representing limited partner interests (the "Common Units") at a price to the public of $14.17 per Common Unit. The Partnership has granted the underwriters a 30-day option to purchase up to 525,000 additional Common Units. The offering is expected to settle and close on June 22, 2015, subject to customary closing conditions. The Partnership intends to use the net proceeds from this offering, including any net proceeds from the underwriters' exercise of their option to purchase additional common units, to repay a portion of the outstanding borrowings under its revolving credit facility. Amounts repaid under our revolving credit facility may be reborrowed to fund our ongoing capital program, potential future acquisitions or for general partnership purposes.

BofA Merrill Lynch, J.P. Morgan, RBC Capital Markets and Wells Fargo Securities are acting as joint book-running managers for the offering. Baird, Stifel, Janney Montgomery Scott and Oppenheimer & Co. are acting as co-managers for the offering. The offering will be made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from:

View data
BofA Merrill Lynch J.P. Morgan 222 Broadway, New York, NY 10038 c/o Broadridge Financial Solutions Attn: Prospectus Department 1155 Long Island Avenue e-mail: dg.prospectus_requests@baml.com Edgewood, NY 11717 Telephone: (866) 803-9204 RBC Capital Markets Wells Fargo Securities Attn: Equity Syndicate Attn: Equity Syndicate Dept. 200 Vesey Street, 8th Floor 375 Park Avenue New York, NY 10281-8098 New York, NY 10152 Phone: 877-822-4089 Email: cmclientsupport@wellsfargo.com Email: equityprospectus@rbccm.com Telephone: 800-326-5897

An electronic copy of the prospectus and prospectus supplement is available from the Securities and Exchange Commission's website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offer is being made only through the prospectus as supplemented, which is part of a shelf registration statement that became effective on April 28, 2015.

Forward Looking Statements

This press release contains forward-looking statements. These forward-looking statements are identified as any statement that does not relate strictly to historical or current facts. In particular, statements, express or implied, concerning future actions, conditions or events, future operating results or the ability to generate revenues, income or cash flow or to make distributions are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions. Future actions, conditions or events and future results of operations of the Partnership may differ materially from those expressed in these forward-looking statements. Many of the factors that will determine these results are beyond the Partnership's ability to control or predict. These statements are necessarily based upon various assumptions involving judgments with respect to the future, including, among others, conditions in the capital and credit markets; the ability to achieve synergies and revenue growth; national, international, regional and local economic, competitive and regulatory conditions and developments; technological developments; inflation rates; interest rates; the political and economic stability of oil producing nations; energy markets; commodity prices; weather conditions; environmental conditions; business and regulatory or legal decisions; the timing and success of business development efforts; terrorism; and other uncertainties. In addition, an extensive list of specific material risks and uncertainties affecting the Partnership is contained in its 2014 Annual Report on Form 10-K and in our other public filings and press releases. There is no assurance that any of the actions, events or results of the forward-looking statements will occur, or if any of them do, what impact they will have on the Partnership's results of operations or financial condition. Because of these uncertainties, you are cautioned not to put undue reliance on any forward-looking statement.

About Azure Midstream Partners, LP

Azure Midstream Partners, LP, headquartered in Dallas, Texas, is a fee-based, growth oriented limited partnership formed to develop, operate, and acquire midstream energy assets. The Partnership provides natural gas gathering, transportation, and processing services; as well as NGL transportation and crude oil logistics services. The Partnership's assets include 723 miles of gathering lines in the horizontal Cotton Valley plays located in east Texas and north Louisiana and are capable of gathering 700 MMcf/d. The Partnership also has two natural gas processing facilities located in Panola County, Texas, and a natural gas processing facility located in Tyler County, Texas with 300 MMcf/d of cumulative processing capacity, two NGL transportation pipelines that connect its Panola County and Tyler County processing facilities to third party NGL pipelines capable of transporting 21,000 barrels per day, and three crude oil transloading facilities containing six crude oil transloaders with capacity to load 22,528 barrels per day.

View data
CONTACT: Institutional Investor Contact: Azure Midstream Partners, LP Eric T. Kalamaras - Chief Financial Officer (214) 206-9499 Retail Investor Contact: Azure Midstream Partners, LP Stephen Ciupak - Director of Financial Strategy (214) 646-1583 Media Relations Contact: Steven C. Sullivan (518) 587-5995

http://media.globenewswire.com/cache/27344/small/34277.jpg

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMzg4NDIjMjczNDQ=

$LFDEF - SOLD @ $3.73 UNTIL FURTHER NOTICE [LINK BACK]

$AZUR - $14.00 -0.140 (-0.99%) Sorry guys...been kind of busy lately and took my eyes off this one for a week [link back] JUST AT THE WRONG TIME...never fear...the offering was priced at $14.17 and the stock is still below that price where we want to buy in...would have been nice to have seen this on the PO announcement and have grabbed some $12.70's but we can't win them all and we have to live our lives am I right?!

Azure Midstream Partners, LP Prices Public Offering of 3,500,000 Common Units

9:29 AM ET 6/17/15 | GlobeNewswire
Azure Midstream Partners, LP (NYSE:AZUR) (the "Partnership") today announced that it has priced its public offering of 3,500,000 common units representing limited partner interests (the "Common Units") at a price to the public of $14.17 per Common Unit. The Partnership has granted the underwriters a 30-day option to purchase up to 525,000 additional Common Units. The offering is expected to settle and close on June 22, 2015, subject to customary closing conditions. The Partnership intends to use the net proceeds from this offering, including any net proceeds from the underwriters' exercise of their option to purchase additional common units, to repay a portion of the outstanding borrowings under its revolving credit facility. Amounts repaid under our revolving credit facility may be reborrowed to fund our ongoing capital program, potential future acquisitions or for general partnership purposes.

BofA Merrill Lynch, J.P. Morgan, RBC Capital Markets and Wells Fargo Securities are acting as joint book-running managers for the offering. Baird, Stifel, Janney Montgomery Scott and Oppenheimer & Co. are acting as co-managers for the offering. The offering will be made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from:

View data
BofA Merrill Lynch J.P. Morgan 222 Broadway, New York, NY 10038 c/o Broadridge Financial Solutions Attn: Prospectus Department 1155 Long Island Avenue e-mail: dg.prospectus_requests@baml.com Edgewood, NY 11717 Telephone: (866) 803-9204 RBC Capital Markets Wells Fargo Securities Attn: Equity Syndicate Attn: Equity Syndicate Dept. 200 Vesey Street, 8th Floor 375 Park Avenue New York, NY 10281-8098 New York, NY 10152 Phone: 877-822-4089 Email: cmclientsupport@wellsfargo.com Email: equityprospectus@rbccm.com Telephone: 800-326-5897

An electronic copy of the prospectus and prospectus supplement is available from the Securities and Exchange Commission's website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offer is being made only through the prospectus as supplemented, which is part of a shelf registration statement that became effective on April 28, 2015.

Forward Looking Statements

This press release contains forward-looking statements. These forward-looking statements are identified as any statement that does not relate strictly to historical or current facts. In particular, statements, express or implied, concerning future actions, conditions or events, future operating results or the ability to generate revenues, income or cash flow or to make distributions are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions. Future actions, conditions or events and future results of operations of the Partnership may differ materially from those expressed in these forward-looking statements. Many of the factors that will determine these results are beyond the Partnership's ability to control or predict. These statements are necessarily based upon various assumptions involving judgments with respect to the future, including, among others, conditions in the capital and credit markets; the ability to achieve synergies and revenue growth; national, international, regional and local economic, competitive and regulatory conditions and developments; technological developments; inflation rates; interest rates; the political and economic stability of oil producing nations; energy markets; commodity prices; weather conditions; environmental conditions; business and regulatory or legal decisions; the timing and success of business development efforts; terrorism; and other uncertainties. In addition, an extensive list of specific material risks and uncertainties affecting the Partnership is contained in its 2014 Annual Report on Form 10-K and in our other public filings and press releases. There is no assurance that any of the actions, events or results of the forward-looking statements will occur, or if any of them do, what impact they will have on the Partnership's results of operations or financial condition. Because of these uncertainties, you are cautioned not to put undue reliance on any forward-looking statement.

About Azure Midstream Partners, LP

Azure Midstream Partners, LP, headquartered in Dallas, Texas, is a fee-based, growth oriented limited partnership formed to develop, operate, and acquire midstream energy assets. The Partnership provides natural gas gathering, transportation, and processing services; as well as NGL transportation and crude oil logistics services. The Partnership's assets include 723 miles of gathering lines in the horizontal Cotton Valley plays located in east Texas and north Louisiana and are capable of gathering 700 MMcf/d. The Partnership also has two natural gas processing facilities located in Panola County, Texas, and a natural gas processing facility located in Tyler County, Texas with 300 MMcf/d of cumulative processing capacity, two NGL transportation pipelines that connect its Panola County and Tyler County processing facilities to third party NGL pipelines capable of transporting 21,000 barrels per day, and three crude oil transloading facilities containing six crude oil transloaders with capacity to load 22,528 barrels per day.

View data
CONTACT: Institutional Investor Contact: Azure Midstream Partners, LP Eric T. Kalamaras - Chief Financial Officer (214) 206-9499 Retail Investor Contact: Azure Midstream Partners, LP Stephen Ciupak - Director of Financial Strategy (214) 646-1583 Media Relations Contact: Steven C. Sullivan (518) 587-5995

http://media.globenewswire.com/cache/27344/small/34277.jpg

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMzg4NDIjMjczNDQ=

F@CK HIM!

$CTIX - $2.93 +0.130 (+4.64%) [LINK BACK]

$NUGT - $9.165 +0.205 (+2.29%) [LINK BACK]

$LFDEF - UrtheCast Corp. to Raise $100 Million of New Capital in Conjunction With Acquisition of the Earth Observation Business of Elecnor, S.A.

5:04 PM ET 6/22/15 | Dow Jones

UrtheCast Corp. to Raise $100 Million of New Capital in Conjunction With Acquisition of the Earth Observation Business of Elecnor, S.A.

Canada NewsWire

VANCOUVER, June 22, 2015

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

VANCOUVER, June 22, 2015 /CNW/ - UrtheCast Corp. (TSX:UR) ("UrtheCast" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Raymond James Ltd. (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 12,500,000 subscription receipts ("Subscription Receipts") at a price of $4.00 per Subscription Receipt (the "Offering Price") for aggregate gross proceeds of CAD$50 million (the "Offering"). UrtheCast also announced today that it has received a binding commitment letter, subject to certain conditions, for a first priority secured term loan in the amount of EUR37.5 million (approximately CAD$52 million) (the "Debt Financing") from a division of a global alternative investment management organization based in New York (the "Lender"). The net proceeds from the Offering and the Debt Financing will be used by UrtheCast to fund, in part, the purchase price of the acquisition of Elecnor, S.A.'s Earth Observation ("EO") business (the "Acquisition"), which is expected to close on or before August 21, 2015. For further details on the Acquisition, see UrtheCast's press release dated June 22, 2015 entitled "UrtheCast To Acquire the Deimos Imaging Earth Observation Business from Elecnor, S.A." or the investor presentation dated June 22, 2015 filed on UrtheCast's SEDAR profile at www.sedar.com.

In addition, the Company has granted the Underwriters an option (the "Over-Allotment Option") to purchase up to an additional 1,875,000 Subscription Receipts at the Offering Price exercisable in whole or in part at any time and from time to time up to 30 days following the Closing Date (as hereinafter defined), for market stabilization purposes and to cover over-allotments, if any. If the Over-Allotment Option is exercised in full, an additional CAD$7.5 million will be raised pursuant to the Offering and the aggregate gross proceeds of the Offering will be CAD$57.5 million.

Subscription Receipts

Each Subscription Receipt will entitle the holder thereof to receive, without payment of additional consideration or further action, one common share of the Company (a "Common Share") in exchange for each Subscription Receipt.

The Subscription Receipts will be issued pursuant to a subscription receipt agreement (the "Subscription Receipt Agreement") to be dated as of the Closing Date, pursuant to which the gross proceeds of the Offering less the Underwriters' expenses and 50% of the Underwriters' commission payable in connection with the Offering (the "Escrowed Proceeds"), will be held in escrow in an interest bearing account pending the closing of the Acquisition. Upon satisfaction or waiver of the conditions to completion of the Acquisition in accordance with the terms of the definitive purchase agreement signed in respect thereof (the "Purchase Agreement"), without amendment or waiver materially adverse to the Company (except for payment of the purchase price and such other conditions that by their nature are to be satisfied at the closing of the Acquisition (the "Escrow Release Conditions"), the remaining 50% of the Underwriters' commission (plus accrued interest) will be released to the Underwriters, the Escrowed Proceeds remaining thereafter will be released to the Company and each Subscription Receipt will be exchanged for one Common Share.

If the Acquisition is not completed prior to 5:00 p.m. (Vancouver time) on the date that is 90 days following the Closing Date, the Purchase Agreement is terminated at an earlier time or UrtheCast advises the subscription receipt agent and Raymond James Ltd., or announces to the public, that it does not intend to proceed with the Acquisition, holders of the Subscription Receipts will receive an amount per Subscription Receipt equal to the Offering Price plus a pro rata share of the interest earned on the Escrowed Proceeds, net of any applicable withholding taxes. To the extent that the Escrowed Proceeds (plus accrued interest) are not sufficient to redeem all of the Subscription Receipts for cancelation at the Offering Price, the Company will contribute such amounts as are necessary to satisfy any shortfall.

The Offering is expected to close on or about July 7, 2015 (the "Closing Date") and is subject to certain conditions, including but not limited to the receipt of all necessary approvals including the approval of the Toronto Stock Exchange.

UrtheCast will file a prospectus supplement to its short form base shelf prospectus in the provinces of Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland and Labrador and its amended and restated short form base shelf prospectus in the provinces of British Columbia, Alberta and Ontario dated May 15, 2015, as may be amended, qualifying the issuance of the Subscription Receipts and the underlying Common Shares issuable upon exchange thereof, including any Subscription Receipts or Common Shares issued pursuant to the exercise of the Over-Allotment Option. The Subscription Receipts may also be offered in the United States on a private placement basis pursuant to an exemption from the registration requirements of the U.S. Securities Act and certain other jurisdictions.

This press release does not constitute an offer of securities for sale in the United States. The Subscription Receipts and the Common Shares issuable upon exchange thereof have not been, and will not be, registered under the U.S. Securities Act and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Debt Financing

The Debt Financing will have a five-year term and is secured by, among other things, a first priority security interest over all of the assets of UrtheCast. Subject to the satisfaction of certain conditions precedent customary for a financing of this type, funds will be available under the Debt Financing by way of a single draw at the closing of the Acquisition.

Funds borrowed under the Debt Financing will accrue interest at a rate equal to the greater of (i) one, three or six month EURIBOR or (ii) 1% plus 9.25%, except that, if UrtheCast elects to repay up to 3% of the interest rate through the addition of this amount to the principal, the rate shall increase to 1% plus 10.25% for the period during which such election applies.

Prepayments will be permitted at UrtheCast's option at any time, subject to payment of, in the case of repayment during (i) the first two years of the term of the Debt Financing, a make-whole payment equal to the sum of all interest payments due during those first two years (including any capitalized interest) plus 3% of the principal being repaid or (ii) the third or fourth years of the term of the Debt Financing, an early termination fee equal to the principal (including any capitalized interest) multiplied by 3% or 1%, respectively.

The commitment letter and related agreements in respect of the Debt Financing contain representations and warranties, affirmative and negative covenants (including requirements for UrtheCast to meet certain financial ratios on an ongoing basis) and events of default that are customary for lending facilities of this nature.

Forward-looking Information

This release contains certain information which, as presented, constitutes "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as "expect" and "intend", statements that an action or event "may" or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements about the timing and closing of the proposed Offering, Debt Financing and Acquisition, the satisfaction of closing conditions in respect thereof and the additional agreements in respect thereof. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of UrtheCast to control or predict, and which may cause UrtheCast's actual results, performance or achievements to be materially different from those expressed or implied thereby, including, but not limited to, risks related to the EO industry and economic factors affecting UrtheCast or the market in general, risks related the inability by UrtheCast or other parties to satisfy conditions to the closing of the Offering, Debt Financing or Acquisition, as well as those factors discussed in the Company's annual information form dated March 20, 2015, (the "AIF") and the Company's short form base shelf prospectus and amended and restated short form base shelf prospectus dated May 11, 2015 (the "Prospectus") which are available under UrtheCast's SEDAR profile at www.sedar.com. Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein, in the AIF and Prospectus, and as otherwise disclosed from time to time on UrtheCast's SEDAR profile. UrtheCast undertakes no obligation to update forward-looking statements except as may be

(MORE TO FOLLOW) Dow Jones Newswires

June 22, 2015 17:04 ET (21:04 GMT)

$LFDEF - UrtheCast Corp. to Raise $100 Million of New Capital in Conjunction With Acquisition of the Earth Observation Business of Elecnor, S.A.

5:04 PM ET 6/22/15 | Dow Jones

UrtheCast Corp. to Raise $100 Million of New Capital in Conjunction With Acquisition of the Earth Observation Business of Elecnor, S.A.

Canada NewsWire

VANCOUVER, June 22, 2015

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

VANCOUVER, June 22, 2015 /CNW/ - UrtheCast Corp. (TSX:UR) ("UrtheCast" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Raymond James Ltd. (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 12,500,000 subscription receipts ("Subscription Receipts") at a price of $4.00 per Subscription Receipt (the "Offering Price") for aggregate gross proceeds of CAD$50 million (the "Offering"). UrtheCast also announced today that it has received a binding commitment letter, subject to certain conditions, for a first priority secured term loan in the amount of EUR37.5 million (approximately CAD$52 million) (the "Debt Financing") from a division of a global alternative investment management organization based in New York (the "Lender"). The net proceeds from the Offering and the Debt Financing will be used by UrtheCast to fund, in part, the purchase price of the acquisition of Elecnor, S.A.'s Earth Observation ("EO") business (the "Acquisition"), which is expected to close on or before August 21, 2015. For further details on the Acquisition, see UrtheCast's press release dated June 22, 2015 entitled "UrtheCast To Acquire the Deimos Imaging Earth Observation Business from Elecnor, S.A." or the investor presentation dated June 22, 2015 filed on UrtheCast's SEDAR profile at www.sedar.com.

In addition, the Company has granted the Underwriters an option (the "Over-Allotment Option") to purchase up to an additional 1,875,000 Subscription Receipts at the Offering Price exercisable in whole or in part at any time and from time to time up to 30 days following the Closing Date (as hereinafter defined), for market stabilization purposes and to cover over-allotments, if any. If the Over-Allotment Option is exercised in full, an additional CAD$7.5 million will be raised pursuant to the Offering and the aggregate gross proceeds of the Offering will be CAD$57.5 million.

Subscription Receipts

Each Subscription Receipt will entitle the holder thereof to receive, without payment of additional consideration or further action, one common share of the Company (a "Common Share") in exchange for each Subscription Receipt.

The Subscription Receipts will be issued pursuant to a subscription receipt agreement (the "Subscription Receipt Agreement") to be dated as of the Closing Date, pursuant to which the gross proceeds of the Offering less the Underwriters' expenses and 50% of the Underwriters' commission payable in connection with the Offering (the "Escrowed Proceeds"), will be held in escrow in an interest bearing account pending the closing of the Acquisition. Upon satisfaction or waiver of the conditions to completion of the Acquisition in accordance with the terms of the definitive purchase agreement signed in respect thereof (the "Purchase Agreement"), without amendment or waiver materially adverse to the Company (except for payment of the purchase price and such other conditions that by their nature are to be satisfied at the closing of the Acquisition (the "Escrow Release Conditions"), the remaining 50% of the Underwriters' commission (plus accrued interest) will be released to the Underwriters, the Escrowed Proceeds remaining thereafter will be released to the Company and each Subscription Receipt will be exchanged for one Common Share.

If the Acquisition is not completed prior to 5:00 p.m. (Vancouver time) on the date that is 90 days following the Closing Date, the Purchase Agreement is terminated at an earlier time or UrtheCast advises the subscription receipt agent and Raymond James Ltd., or announces to the public, that it does not intend to proceed with the Acquisition, holders of the Subscription Receipts will receive an amount per Subscription Receipt equal to the Offering Price plus a pro rata share of the interest earned on the Escrowed Proceeds, net of any applicable withholding taxes. To the extent that the Escrowed Proceeds (plus accrued interest) are not sufficient to redeem all of the Subscription Receipts for cancelation at the Offering Price, the Company will contribute such amounts as are necessary to satisfy any shortfall.

The Offering is expected to close on or about July 7, 2015 (the "Closing Date") and is subject to certain conditions, including but not limited to the receipt of all necessary approvals including the approval of the Toronto Stock Exchange.

UrtheCast will file a prospectus supplement to its short form base shelf prospectus in the provinces of Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland and Labrador and its amended and restated short form base shelf prospectus in the provinces of British Columbia, Alberta and Ontario dated May 15, 2015, as may be amended, qualifying the issuance of the Subscription Receipts and the underlying Common Shares issuable upon exchange thereof, including any Subscription Receipts or Common Shares issued pursuant to the exercise of the Over-Allotment Option. The Subscription Receipts may also be offered in the United States on a private placement basis pursuant to an exemption from the registration requirements of the U.S. Securities Act and certain other jurisdictions.

This press release does not constitute an offer of securities for sale in the United States. The Subscription Receipts and the Common Shares issuable upon exchange thereof have not been, and will not be, registered under the U.S. Securities Act and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Debt Financing

The Debt Financing will have a five-year term and is secured by, among other things, a first priority security interest over all of the assets of UrtheCast. Subject to the satisfaction of certain conditions precedent customary for a financing of this type, funds will be available under the Debt Financing by way of a single draw at the closing of the Acquisition.

Funds borrowed under the Debt Financing will accrue interest at a rate equal to the greater of (i) one, three or six month EURIBOR or (ii) 1% plus 9.25%, except that, if UrtheCast elects to repay up to 3% of the interest rate through the addition of this amount to the principal, the rate shall increase to 1% plus 10.25% for the period during which such election applies.

Prepayments will be permitted at UrtheCast's option at any time, subject to payment of, in the case of repayment during (i) the first two years of the term of the Debt Financing, a make-whole payment equal to the sum of all interest payments due during those first two years (including any capitalized interest) plus 3% of the principal being repaid or (ii) the third or fourth years of the term of the Debt Financing, an early termination fee equal to the principal (including any capitalized interest) multiplied by 3% or 1%, respectively.

The commitment letter and related agreements in respect of the Debt Financing contain representations and warranties, affirmative and negative covenants (including requirements for UrtheCast to meet certain financial ratios on an ongoing basis) and events of default that are customary for lending facilities of this nature.

Forward-looking Information

This release contains certain information which, as presented, constitutes "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as "expect" and "intend", statements that an action or event "may" or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements about the timing and closing of the proposed Offering, Debt Financing and Acquisition, the satisfaction of closing conditions in respect thereof and the additional agreements in respect thereof. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of UrtheCast to control or predict, and which may cause UrtheCast's actual results, performance or achievements to be materially different from those expressed or implied thereby, including, but not limited to, risks related to the EO industry and economic factors affecting UrtheCast or the market in general, risks related the inability by UrtheCast or other parties to satisfy conditions to the closing of the Offering, Debt Financing or Acquisition, as well as those factors discussed in the Company's annual information form dated March 20, 2015, (the "AIF") and the Company's short form base shelf prospectus and amended and restated short form base shelf prospectus dated May 11, 2015 (the "Prospectus") which are available under UrtheCast's SEDAR profile at www.sedar.com. Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein, in the AIF and Prospectus, and as otherwise disclosed from time to time on UrtheCast's SEDAR profile. UrtheCast undertakes no obligation to update forward-looking statements except as may be

(MORE TO FOLLOW) Dow Jones Newswires

June 22, 2015 17:04 ET (21:04 GMT)

$LFDEF - UrtheCast To Acquire the Deimos Imaging Earth Observation Business from Elecnor, S.A.

4:36 PM ET 6/22/15 | Dow Jones

UrtheCast To Acquire the Deimos Imaging Earth Observation Business from Elecnor, S.A.

Canada NewsWire

VANCOUVER, June 22, 2015

UrtheCast to acquire ownership and operation of the Deimos-1 and Deimos-2 satellites, satellite operations and their global archive.

VANCOUVER, June 22, 2015 /CNW/ - UrtheCast Corp. (TSX:UR) ("UrtheCast" or the "Company"), today announced that its subsidiary has entered into a definitive agreement with Elecnor, S.A. ("Elecnor") to acquire Elecnor's Earth Observation business dba Deimos Imaging (the "Acquisition") for an aggregate price of EUR74.2 million, subject to customary working capital adjustments, with EUR69 million due at closing and EUR5.2 million to be paid over the next five years. To carry out the Acquisition, UrtheCast's wholly-owned subsidiary, UrtheCast International Corp., has entered into a share purchase agreement with Elecnor and Deimos Space, S.L.U. to acquire the outstanding shares of Deimos Imaging, S.L.U. and DOT Imaging, S.L.U. (collectively, "DOT-Deimos"). DOT-Deimos owns and operates two satellites, Deimos-1 and Deimos-2. Subject to satisfaction of certain customary closing conditions, the Acquisition is expected to close on or before August 21, 2015, along with the execution of certain ancillary agreements.

"This is an incredible acquisition that epitomizes technological and operational synergy," explained Scott Larson, UrtheCast Co-founder and Chief Executive Officer. "By adding these satellites to our suite of sensors available via our web platform, significantly expanding our space operations capability - important for our recently announced SAR and Optical constellation - and merging our business development, UrtheCast is rapidly accelerating its mission to democratize Earth Observation imagery, and bring a unique dataset and distribution model to customers and users that up until now, has not been available anywhere in the marketplace."

Acquired Business

The acquired business of DOT-Deimos comprises the Earth Observation ("EO") satellite and imagery business of Elecnor, a publicly traded Spanish engineering and infrastructure company, which has been producing imagery since the launch and commissioning of the Deimos-1 satellite in 2009. The business consists of, among other things, the ownership and operation of the Deimos-1 and Deimos-2 EO satellites and the collection, storage, processing, analysis, distribution and licensing of the EO imagery captured by these and other satellites. DOT-Deimos has an established customer base across Europe and Latin America, including the European Space Agency ("ESA"), European governmental agencies and commercial customers in the agricultural, forestry and land use industries, among others. Currently, DOT-Deimos has approximately 50 employees with expertise in the EO industry. Upon closing the Acquisition, UrtheCast will also own the full imagery archive utilized by the acquired business, which currently consists of approximately 6.5 billion square kilometres.

Fabrizio Pirondini, Deimos Co-founder and Chief Executive Officer, added: "This is a superb opportunity for all involved, and opens up a world of possibilities for our respective sales teams. The sale of EO data and value-added services is at the core of our operations, such that our synergies and objectives for this acquisition are perfectly aligned."

The Deimos-1 satellite was launched in 2009 and provides 22-metre resolution images at 10 bits with a swath width of 650 kilometres. Deimos-1 has a collection capacity of more than 5,000,000 square-kilometres per day, with a three-day average revisit time worldwide. The Deimos-2 satellite was launched in 2014 and provides 75 cm pan-sharpened images with a swath width of 12 kilometres. Deimos-2 has a collection capacity of more than 150,000 square-kilometres per day, with a two-day average revisit time worldwide.

The combination of UrtheCast and DOT-Deimos is expected to allow UrtheCast to accelerate its own strategy. UrtheCast believes this will be achieved through the use of Deimos' imagery archive on UrtheCast's web platform, distributing fresh imagery through UrtheCast's established distribution channels, customers and web platform, leveraging each company's established relationships and building upon each other's infrastructure.

In addition, UrtheCast and Deimos Space have signed a Mutual Cooperation Agreement that will allow both companies to look for opportunities in the market for the benefit of both companies. Deimos Space will be the exclusive provider for receiving stations for the Deimos-1 and Deimos-2 satellites. Also, under this agreement, the companies will work together on UrtheCast's recently announced optical and SAR satellite constellation in the areas of the headquarter mission control centre, direct tasking and receive ground stations, mission analysis and flight dynamics, and in the integration and testing of the SAR payloads.

Conference Call and Webcast Information

UrtheCast will hold a conference call on June 22, 2015 at 4:30 p.m. ET. To access this conference call, please dial (416) 695-7806 or (888) 789-9572 and use the pass code 9618732. An archive of the conference call will be available on our website the following day.

Advisors

Raymond James Ltd. has acted as financial advisor to UrtheCast in connection with the Acquisition and has provided a fairness opinion to the Board of Directors.

About UrtheCast Corp.

UrtheCast Corp. is a Vancouver-based technology company that is developing the world's first Ultra HD video feed of Earth, streamed from space in full color. Working with prominent aerospace partners from across the globe, UrtheCast has built, launched, installed, and will soon operate its Ultra HD video camera, Iris, on the ISS alongside its Medium Resolution Camera ("MRC") which reached Initial Operation Capability ("IOC") in 2014. Video and still image data captured by the cameras will be downlinked to ground stations across the planet and displayed on the UrtheCast web platform, or distributed directly to partners and customers. UrtheCast's cameras will provide Ultra HD video and still imagery of Earth that will allow for monitoring of the environment, humanitarian relief, social events, agricultural land, etc. Common shares of UrtheCast trade on the Toronto Stock Exchange as ticker 'UR'.

For more information visit UrtheCast's website at www.urthecast.com.

About UrtheCast's high-resolution camera Iris

UrtheCast's High-Resolution Camera, Iris, is a multispectral imager mounted on a bi-axial pointing platform that provides a pitch/roll pointing capability to image points between +/-52 degrees latitude. This allows it to capture full-color video sequences that are approximately 1m GSD and approximately 60 seconds in length through a wide range of oblique-look angles. The image size for the Video is approximately 5.5 x 3.5 km.

About UrtheCast's medium-resolution camera Theia

UrtheCast's MRC, Theia, is a conventional linear Charge-Coupled Device (CCD) pushbroom camera. It produces strips of medium-resolution, 4-channel multispectral imagery with a GSD of approximately 5m and a swath width of approximately 50km. Theia's daily collection capability is approximately 29-million km(2).

Forward Looking Information

This release contains certain information which, as presented, constitutes "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as "believe", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements about the closing of the Acquisition and the satisfaction of closing conditions required therefor, the ability of UrtheCast to finance of the Acquisition, the expected benefits of completing the Acquisition, the expected lifetimes of the Deimos-1 and Deimos-2 satellites, UrtheCast's expectations with respect to the operations of UrtheCast and Deimos following closing of the Acquisition, commissioning of Iris, plans to operate camera components on, and stream video footage from, the ISS, proposed image and video product offerings, expectations regarding the growth of commercial operations and expected partners and customers to distribute such products. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of UrtheCast to control or predict, and which may cause UrtheCast's or Deimos' actual results, performance or achievements to be materially different from those expressed or implied thereby, including, but not limited to, UrtheCast, Elecnor or Deimos Space Imaging, S.L.U. being unable to satisfy the conditions to closing the Acquisition, UrtheCast not realizing the expected strategic benefits of the Acquisition, undisclosed liabilities of the acquired business of DOT-Deimos, risks related to integration of UrtheCast and the acquired business of Deimos, risks related to the increased indebtedness of UrtheCast following payment of the purchase price of the Acquisition, the inability of UrtheCast to finance the purchase price of the Acquisition, risks related to the potential for regulatory review and unwinding of the Acquisition, risks related to the provision of Elecnor or its affiliates of transition services following completion of the Acquisition or their termination of such services, damage which may have occurred to UrtheCast's cameras during launch or installation, delays in the Iris commissioning process, unexpected changes in Russian, Canadian or European government policies, as well as those factors discussed in the Company's annual information form dated March 20, 2015, (the "AIF") and the Company's amended and restated short form base shelf prospectus dated May 11, 2015 (the "Prospectus") which are available under UrtheCast's SEDAR profile at www.sedar.com.

(MORE TO FOLLOW) Dow Jones Newswires

June 22, 2015 16:36 ET (20:36 GMT)

$LFDEF - UrtheCast To Acquire the Deimos Imaging Earth Observation Business from Elecnor, S.A.

4:36 PM ET 6/22/15 | Dow Jones

UrtheCast To Acquire the Deimos Imaging Earth Observation Business from Elecnor, S.A.

Canada NewsWire

VANCOUVER, June 22, 2015

UrtheCast to acquire ownership and operation of the Deimos-1 and Deimos-2 satellites, satellite operations and their global archive.

VANCOUVER, June 22, 2015 /CNW/ - UrtheCast Corp. (TSX:UR) ("UrtheCast" or the "Company"), today announced that its subsidiary has entered into a definitive agreement with Elecnor, S.A. ("Elecnor") to acquire Elecnor's Earth Observation business dba Deimos Imaging (the "Acquisition") for an aggregate price of EUR74.2 million, subject to customary working capital adjustments, with EUR69 million due at closing and EUR5.2 million to be paid over the next five years. To carry out the Acquisition, UrtheCast's wholly-owned subsidiary, UrtheCast International Corp., has entered into a share purchase agreement with Elecnor and Deimos Space, S.L.U. to acquire the outstanding shares of Deimos Imaging, S.L.U. and DOT Imaging, S.L.U. (collectively, "DOT-Deimos"). DOT-Deimos owns and operates two satellites, Deimos-1 and Deimos-2. Subject to satisfaction of certain customary closing conditions, the Acquisition is expected to close on or before August 21, 2015, along with the execution of certain ancillary agreements.

"This is an incredible acquisition that epitomizes technological and operational synergy," explained Scott Larson, UrtheCast Co-founder and Chief Executive Officer. "By adding these satellites to our suite of sensors available via our web platform, significantly expanding our space operations capability - important for our recently announced SAR and Optical constellation - and merging our business development, UrtheCast is rapidly accelerating its mission to democratize Earth Observation imagery, and bring a unique dataset and distribution model to customers and users that up until now, has not been available anywhere in the marketplace."

Acquired Business

The acquired business of DOT-Deimos comprises the Earth Observation ("EO") satellite and imagery business of Elecnor, a publicly traded Spanish engineering and infrastructure company, which has been producing imagery since the launch and commissioning of the Deimos-1 satellite in 2009. The business consists of, among other things, the ownership and operation of the Deimos-1 and Deimos-2 EO satellites and the collection, storage, processing, analysis, distribution and licensing of the EO imagery captured by these and other satellites. DOT-Deimos has an established customer base across Europe and Latin America, including the European Space Agency ("ESA"), European governmental agencies and commercial customers in the agricultural, forestry and land use industries, among others. Currently, DOT-Deimos has approximately 50 employees with expertise in the EO industry. Upon closing the Acquisition, UrtheCast will also own the full imagery archive utilized by the acquired business, which currently consists of approximately 6.5 billion square kilometres.

Fabrizio Pirondini, Deimos Co-founder and Chief Executive Officer, added: "This is a superb opportunity for all involved, and opens up a world of possibilities for our respective sales teams. The sale of EO data and value-added services is at the core of our operations, such that our synergies and objectives for this acquisition are perfectly aligned."

The Deimos-1 satellite was launched in 2009 and provides 22-metre resolution images at 10 bits with a swath width of 650 kilometres. Deimos-1 has a collection capacity of more than 5,000,000 square-kilometres per day, with a three-day average revisit time worldwide. The Deimos-2 satellite was launched in 2014 and provides 75 cm pan-sharpened images with a swath width of 12 kilometres. Deimos-2 has a collection capacity of more than 150,000 square-kilometres per day, with a two-day average revisit time worldwide.

The combination of UrtheCast and DOT-Deimos is expected to allow UrtheCast to accelerate its own strategy. UrtheCast believes this will be achieved through the use of Deimos' imagery archive on UrtheCast's web platform, distributing fresh imagery through UrtheCast's established distribution channels, customers and web platform, leveraging each company's established relationships and building upon each other's infrastructure.

In addition, UrtheCast and Deimos Space have signed a Mutual Cooperation Agreement that will allow both companies to look for opportunities in the market for the benefit of both companies. Deimos Space will be the exclusive provider for receiving stations for the Deimos-1 and Deimos-2 satellites. Also, under this agreement, the companies will work together on UrtheCast's recently announced optical and SAR satellite constellation in the areas of the headquarter mission control centre, direct tasking and receive ground stations, mission analysis and flight dynamics, and in the integration and testing of the SAR payloads.

Conference Call and Webcast Information

UrtheCast will hold a conference call on June 22, 2015 at 4:30 p.m. ET. To access this conference call, please dial (416) 695-7806 or (888) 789-9572 and use the pass code 9618732. An archive of the conference call will be available on our website the following day.

Advisors

Raymond James Ltd. has acted as financial advisor to UrtheCast in connection with the Acquisition and has provided a fairness opinion to the Board of Directors.

About UrtheCast Corp.

UrtheCast Corp. is a Vancouver-based technology company that is developing the world's first Ultra HD video feed of Earth, streamed from space in full color. Working with prominent aerospace partners from across the globe, UrtheCast has built, launched, installed, and will soon operate its Ultra HD video camera, Iris, on the ISS alongside its Medium Resolution Camera ("MRC") which reached Initial Operation Capability ("IOC") in 2014. Video and still image data captured by the cameras will be downlinked to ground stations across the planet and displayed on the UrtheCast web platform, or distributed directly to partners and customers. UrtheCast's cameras will provide Ultra HD video and still imagery of Earth that will allow for monitoring of the environment, humanitarian relief, social events, agricultural land, etc. Common shares of UrtheCast trade on the Toronto Stock Exchange as ticker 'UR'.

For more information visit UrtheCast's website at www.urthecast.com.

About UrtheCast's high-resolution camera Iris

UrtheCast's High-Resolution Camera, Iris, is a multispectral imager mounted on a bi-axial pointing platform that provides a pitch/roll pointing capability to image points between +/-52 degrees latitude. This allows it to capture full-color video sequences that are approximately 1m GSD and approximately 60 seconds in length through a wide range of oblique-look angles. The image size for the Video is approximately 5.5 x 3.5 km.

About UrtheCast's medium-resolution camera Theia

UrtheCast's MRC, Theia, is a conventional linear Charge-Coupled Device (CCD) pushbroom camera. It produces strips of medium-resolution, 4-channel multispectral imagery with a GSD of approximately 5m and a swath width of approximately 50km. Theia's daily collection capability is approximately 29-million km(2).

Forward Looking Information

This release contains certain information which, as presented, constitutes "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as "believe", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements about the closing of the Acquisition and the satisfaction of closing conditions required therefor, the ability of UrtheCast to finance of the Acquisition, the expected benefits of completing the Acquisition, the expected lifetimes of the Deimos-1 and Deimos-2 satellites, UrtheCast's expectations with respect to the operations of UrtheCast and Deimos following closing of the Acquisition, commissioning of Iris, plans to operate camera components on, and stream video footage from, the ISS, proposed image and video product offerings, expectations regarding the growth of commercial operations and expected partners and customers to distribute such products. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of UrtheCast to control or predict, and which may cause UrtheCast's or Deimos' actual results, performance or achievements to be materially different from those expressed or implied thereby, including, but not limited to, UrtheCast, Elecnor or Deimos Space Imaging, S.L.U. being unable to satisfy the conditions to closing the Acquisition, UrtheCast not realizing the expected strategic benefits of the Acquisition, undisclosed liabilities of the acquired business of DOT-Deimos, risks related to integration of UrtheCast and the acquired business of Deimos, risks related to the increased indebtedness of UrtheCast following payment of the purchase price of the Acquisition, the inability of UrtheCast to finance the purchase price of the Acquisition, risks related to the potential for regulatory review and unwinding of the Acquisition, risks related to the provision of Elecnor or its affiliates of transition services following completion of the Acquisition or their termination of such services, damage which may have occurred to UrtheCast's cameras during launch or installation, delays in the Iris commissioning process, unexpected changes in Russian, Canadian or European government policies, as well as those factors discussed in the Company's annual information form dated March 20, 2015, (the "AIF") and the Company's amended and restated short form base shelf prospectus dated May 11, 2015 (the "Prospectus") which are available under UrtheCast's SEDAR profile at www.sedar.com.

(MORE TO FOLLOW) Dow Jones Newswires

June 22, 2015 16:36 ET (20:36 GMT)

$CVOL - $0.51 -0.0067 (-1.30%) [link back] L2 showing it's at $0.5799 +0.06 (+12.23) on a 4 share buy...hahaha!

My bid at $0.50 is in

$CTIX - $2.90 +0.100 (+3.57%)

Added more NUGT @ $8.96

$LJPC - $22.177 -0.0726 (-0.33%) weeeeeeeeeeee! [LINK BACK]

$LFDEF - bam!!!!!!!! 100,000 SHARE TRADE JUST NOW @ $3.8028...[ not mine ]

Wall Street Analysts Have $15.5 Price Target on TiVo Inc. (NASDAQ:TIVO)

http://www.themarketsdaily.com/wall-street-analysts-have-15-5-price-target-on-tivo-inc-nasdaqtivo/30941/

$LFDEF - $3.88 +0.4974 (+14.71%) [link back] weeeeeeeeeee!

When bounce worthy news will come you can expect moves of 60-150% on above average volume...

I'm waiting patiently.

Yes but tell that to all the insiders who've dumped millions of dollars in stock...WTF?!

Activision deal

Very interesting
http://www.dakotafinancialnews.com/erickson-pt-raised-to-7-00-at-imperial-capital-eac/212208/

http://www.octafinance.com/erickson-air-crane-nasdaqeac-has-48-62-upside-after-tp-raise-at-imperial-capital/

$ONVO - Organovo Holdings, Inc. Prices $40 Million Public Offering of Common Stock

8:56 AM ET 6/18/15 | PR Newswire

Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo" or the "Company") today announced the sale of 9,425,000 shares of its common stock in an underwritten public offering at a price to the public of $4.25 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,413,750 shares of common stock on the same terms and conditions. The gross offering proceeds to Organovo from the sale of the shares are expected to be $40,056,250, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding any proceeds from the exercise of the underwriters' option. The offering is expected to close on or about June 23, 2015, subject to customary closing conditions.

The Company anticipates using the net proceeds from this offering for general corporate purposes, including research and development, the development and commercialization of its products, general administrative expenses, license or technology acquisitions, and working capital and capital expenditures.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. is acting as a co-manager for the offering.

The shares described above will be offered pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission ("SEC"). Organovo intends to file a final prospectus supplement relating to the offering with the SEC, which will be available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained by sending a request to: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, New York 10022, by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-503-4611, or by e-mailing prospectus@pjc.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Organovo, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo believes these 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on the Company's current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the ability to complete the proposed offering; risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance of the Company's products; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its annual report on Form 10-K filed with the SEC on June 9, 2015, its preliminary prospectus supplement filed with the SEC on June 17, 2015, its final prospectus supplement to be filed with the SEC and its other filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

Barry Michaels, Chief Financial Officer, (858) 224-1000 ext. 3, IR@organovo.com

Gerry Amato, Amato and Partners, LLC, Investor Relations Counsel, admin@amatoandpartners.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/organovo-holdings-inc-prices-40-million-public-offering-of-common-stock-300101334.html

SOURCE Organovo Holdings, Inc.

$ONVO - Organovo Holdings, Inc. Prices $40 Million Public Offering of Common Stock

8:56 AM ET 6/18/15 | PR Newswire

Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo" or the "Company") today announced the sale of 9,425,000 shares of its common stock in an underwritten public offering at a price to the public of $4.25 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,413,750 shares of common stock on the same terms and conditions. The gross offering proceeds to Organovo from the sale of the shares are expected to be $40,056,250, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding any proceeds from the exercise of the underwriters' option. The offering is expected to close on or about June 23, 2015, subject to customary closing conditions.

The Company anticipates using the net proceeds from this offering for general corporate purposes, including research and development, the development and commercialization of its products, general administrative expenses, license or technology acquisitions, and working capital and capital expenditures.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. is acting as a co-manager for the offering.

The shares described above will be offered pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission ("SEC"). Organovo intends to file a final prospectus supplement relating to the offering with the SEC, which will be available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained by sending a request to: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, New York 10022, by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-503-4611, or by e-mailing prospectus@pjc.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Organovo, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo believes these 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on the Company's current expectations, but are subject to a number of risks and uncertainties. The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the ability to complete the proposed offering; risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance of the Company's products; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its annual report on Form 10-K filed with the SEC on June 9, 2015, its preliminary prospectus supplement filed with the SEC on June 17, 2015, its final prospectus supplement to be filed with the SEC and its other filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

Barry Michaels, Chief Financial Officer, (858) 224-1000 ext. 3, IR@organovo.com

Gerry Amato, Amato and Partners, LLC, Investor Relations Counsel, admin@amatoandpartners.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/organovo-holdings-inc-prices-40-million-public-offering-of-common-stock-300101334.html

SOURCE Organovo Holdings, Inc.

ZZZZZZZZZZZZZzzzzzzzzzzzzzzzzzz

Was not in it for this...missed it completely

You can get some SPXS under $17.50 now...guess the SPX wants to be above 2120 today

dude!!!!!!!!

DAmnit!!!!!!!!!! Shit!!!!!!!!! Totally missed this!!!!

Radius Announces Positive Top-Line Data From ACTIVExtend Trial Including Combined 25 Month Results

8:03 PM ET 6/17/15 | GlobeNewswire

Investigational drug abaloparatide-SC shows continued clinical benefit across the 25-month period with significant reductions in vertebral, nonvertebral, clinical and major osteoporotic fractures.

In the first six months of ACTIVExtend, patients who previously completed 18 months of abaloparatide-SC administration experienced no new vertebral fractures.

Radius believes that the positive results from the ACTIVE and ACTIVExtend trials have met the primary and secondary endpoints essential for submission of the NDA and MAA in 2015.

Company to Host Webcast Tomorrow (Thursday, June 18, 2015) at 8:30 a.m. ET

Radius Health, Inc. (Nasdaq:RDUS) reports top line data from the first six months of ACTIVExtend and the 25 month combined data from ACTIVE and ACTIVExtend. Additionally, Radius is reporting new data from an exploratory analysis of major osteoporotic fractures in the ACTIVE trial.

Radius previously reported positive results in December 2014 for the Phase 3 ACTIVE Trial - meeting the primary endpoint of new vertebral fracture reduction (-86%, p < 0.0001) and secondary endpoints of non-vertebral fracture reduction (-43%, p = 0.0489) and BMD increases at Spine (18M, 9.20% p < 0.0001), Femoral Neck (18M 2.90% p < 0.0001) and Total Hip (18M 3.44% p < 0.0001).

ACTIVExtend results show that the group previously treated with abaloparatide had no new vertebral fractures during the first six months on alendronate. From the start of the ACTIVE study, this group showed an 87% reduction in new vertebral fractures (p < 0.0001), 52% reduction in non-vertebral fractures (p = 0.0168), 48% reduction in clinical fractures (p = 0.0139), and a 58% reduction in major osteoporotic fractures (p = 0.0122) over the 25-month period. A recent exploratory analysis of the ACTIVE trial showed that, for major osteoporotic fractures, there was a 67% reduction in major osteoporotic fractures (p = 0.0014) for the abaloparatide treatment group versus placebo, and a 53% reduction in major osteoporotic fractures (p = 0.0437) for the abaloparatide treatment group as compared to teriparatide.

Over the 25-month period, patients in the abaloparatide-alendronate treatment group on average achieved a 12.8% increase in BMD at the lumbar spine, a 5.5% increase in BMD at total hip, and a 4.5% increase in BMD at the femoral neck. In this treatment group, 20.4% of patients achieved a 6% increase or greater in BMD at all three sites (i.e., lumbar spine, total hip, and femoral neck).

The adverse events reported during the alendronate treatment period were consistent with previous clinical experience.

View data
Prior Placebo Prior Abaloparatide Arthralgia 4.7% 4.3% Dyspepsia 2.2% 2.7% Upper respiratory infection 4.5% 2.5% Urinary tract infection 1.0% 2.4% Bone pain 1.2% 2.2%

"We are extremely pleased with the consistency of the positive results of both the ACTIVE and ACTIVExtend trials, which support the potential use of abaloparatide for the treatment of postmenopausal osteoporosis," said Robert E. Ward, Radius President and Chief Executive Officer. "We are excited about continuing our active dialogue with health authorities as we prepare our regulatory submissions."

Osteoporosis is a major public health concern with substantial health and economic burden. The International Osteoporosis Foundation estimates that over 200 million people worldwide suffer from osteoporosis causing more than 8.9 million fractures annually, or one every three seconds. In the US alone, there are over 2 million fractures annually, and they are most prevalent at the hip, spine and wrist. The majority of osteoporosis patients remain undiagnosed and undertreated, and there is an unmet medical need for incident non-vertebral fractures which currently represent 73% of all fractures, and for which current therapies are considered inadequate.

There are two categories of osteoporosis medications: antiresorptive medications that slow bone loss and anabolic drugs that increase the rate of bone formation. Bisphosphonates, calcitonin, denosumab, estrogen and estrogen agonists/antagonists are antiresorptive medicines and slow bone loss. Teriparatide, a form of parathyroid hormone, is an anabolic drug, and currently the only osteoporosis medicine approved by the FDA that rebuilds bone. In 2014, global sales of osteoporosis therapies totaled $6.4 billion, $2.3 billion of which was for injectable drugs.

About ACTIVExtend

ACTIVExtend is an extension study to evaluate 24 months of standard-of-care osteoporosis management following completion of 18 months of abaloparatide-SC or placebo treatment in the Phase 3 ACTIVE trial.

About ACTIVE Results

On the primary endpoint of reduction of new vertebral fractures, abaloparatide-SC (n=690, fracture rate 0.58%) achieved a statistically significant 86% reduction as compared to the placebo-treated group (n=711, fracture rate 4.22%) (p<0.0001). The open-label teriparatide injection treatment group (n=717, fracture rate 0.84%) showed a statistically significant 80% reduction of new vertebral fractures (excluding worsening) as compared to the placebo-treated group (p<0.0001). For the secondary endpoint of non-vertebral fractures, abaloparatide-SC (n=824, Kaplan-Meier estimated, or KM, fracture rate 2.7%) achieved a statistically significant reduction compared to the placebo-treated group (n=821, KM fracture rate 4.7%), and the hazard ratio for abaloparatide vs. placebo was 0.57 (p=0.0489); the open label teriparatide injection treatment group (n=818, KM fracture rate 3.3%) had a hazard ratio of 0.72 (NS) compared to the placebo-treated group.

Abaloparatide-SC treated patients had a statistically significant reduction in major osteoporotic fractures versus both placebo and teriparatide, of 67% and 53% respectively, and a statistically significant reduction of 72% in wrist fractures versus teriparatide.

The results from the ACTIVE and ACTIVExtend trials, together with the entire data set from the abaloparatide development program, are subject to regulatory review. Health authorities are the final arbiter of comparative claims against an active comparator that is an approved drug product with approved labeling.

About Radius

Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, which is completing Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for the treatment of osteoporosis and the investigational drug RAD1901 for the treatment of hormone driven, or hormone resistant, metastatic breast cancer. www.radiuspharm.com

About the Investigational Drug Abaloparatide

Radius' investigational drug abaloparatide is a synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP), a naturally occurring bone-building hormone that we believe has the potential to increase bone mineral density by stimulating new bone formation. Abaloparatide-SC is an investigational drug currently completing Phase 3 development for potential use as a daily self-administered injection for the treatment of patients with postmenopausal osteoporosis at high risk of fracture. Radius also is developing the investigational drug abaloparatide-TD for potential use as a short wear-time transdermal patch designed to administer abaloparatide without the need for subcutaneous injection based on 3M's patented Microstructured Transdermal System technology.

Conference Call Information:

Date: Thursday, June 18, 2015

Time: 8:30 a.m. ET

Domestic Dial-in Number: 1-877-705-6003

International Dial-in Number: 1-201-493-6725

Live webcast: http://public.viavid.com/player/index.php?id=115018

A live audio webcast of the call also will be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for an additional 30 days on the Radius website, www.radiuspharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding expectations for abaloparatide, including without limitation, expectations regarding the clinical significance and regulatory review of data from our Phase 3 ACTIVE study and from our ACTIVExtend study, regulatory submissions seeking approval of abaloparatide-SC and the potential therapeutic benefits of abaloparatide-SC for patients.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our dependence on the success of abaloparatide-SC, and our inability to ensure that abaloparatide-SC will obtain regulatory approval in the timeframe anticipated or at all or be successfully commercialized; we have no product revenues; our need for additional funding, which may not be available; we are not currently profitable and may never become profitable; restrictions imposed on our business by our credit facility, and risks related to default on our obligations under our credit facility; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; risks related to clinical trials, including having most of our products in early stage clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates; product candidates for which we obtain marketing approval, if any, could be subject to restrictions or withdrawal from the market and we may be subject to penalties; failure to achieve market acceptance of our product candidates; risks related to the use of our limited resources on particular product candidates and not others; delays in enrollment of patients in our clinical trials, which could delay or prevent regulatory approvals; the dependence of our drug development program upon third-parties who are outside our control; the risk that a regulatory or government official will determine that third-parties with a financial interest in the outcome of the Phase 3 study of abaloparatide-SC affected the reliability of the data from the study; our reliance on third parties to formulate and manufacture our product candidates; failure to establish additional collaborations; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; developments by competitors may render our products or technologies obsolete or non-competitive; risks related to the fact that our drugs may sell for inadequate prices or patients may be unable to obtain adequate reimbursement; effects of product liability lawsuits on commercialization of our products; failure to comply with obligations of our intellectual property licenses; failure to protect our intellectual property or failure to secure necessary intellectual property related to abaloparatide-SC, abaloparatide-TD, RAD-1901 and/or RAD-140; our or our licensors' inability to obtain and maintain patent protection for technology and products; risks related to our compliance with patent application requirements; failure to protect the confidentiality of our trade secrets; risks related to our infringement of third parties' rights; risks related to employees' disclosure of former employers' trade secrets; risks associated with intellectual property litigation, including expending substantial resources and distracting personnel from their normal responsibilities; risks associated with healthcare reform; our failure to comply with healthcare laws and regulations; our exposure to claims associated with the use of hazardous materials and chemicals; inability to successfully manage our growth; risks relating to business combinations and acquisitions; our reliance on key executive officers and advisors; our inability to hire additional qualified personnel; volatility in the price of our common stock; capital appreciation is the only source of gain for our common stock; risks related to increased costs and compliance initiatives associated with operating as a public company; our directors, executive officers and principal stockholders have substantial control over us and could delay or prevent a change in control; future sales of our common stock could depress the price of our common stock; inaccurate or unfavorable information about us could cause the price of our common stock to decline; provisions in our charter documents and Delaware law could discourage takeover attempts; and our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 10, 2015, and our most recent quarterly and other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Investor Relations
Barbara Ryan
Investor Relations
Radius Health, Inc.
203-274-2825
bryan@radiuspharm.com

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMzg5NDAjMzExNDk=

shit!!!!!!

PLUG...ohhhh the memories!

All good things and possibilities...however it will be a while before anything is fitted into an Apple watch that actually works...in the meantime it would be nice if Apple were to take over ECTE and finance the sh!t out of them!

As I suspected [link back]...$CVOL - $0.54 -0.0368 (-6.38%)...I will have a bid in the $0.50xx's